Compare Analog Devices, Inc. (ADI) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Analog Devices, Inc. vs ARK Genomic Revolution ETF — how do they compare? Analog Devices, Inc. trades at $388.09 (market cap $184.62B), while ARK Genomic Revolution ETF trades at $41.15. The key difference: Analog Devices, Inc. pays a 1.16% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Analog Devices, Inc. nearer its low. Which is the better fit depends on your goals.
| ADI | ARKG | |
|---|---|---|
Market Cap | $184.62B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $445.48 | $43.57 |
52-Week Low | $220.68 | $23.09 |
Enterprise Value | $189.87B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $379.03, up 0.5% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q3-Q1 2026) and robust profitability (26% net margin). Recent acquisition of Empower Semiconductor and AI-driven semiconductor demand provide growth catalysts. Cash flow remains positive at $508M in 2025, though net cash flow is projected to decline to $61M in 2026.
Outlook remains positive with 79.6% analyst buy ratings and $471 consensus price target (24% upside). Key risks include elevated valuation multiples (P/E 57.9) and debt-to-asset ratio increase to 17.9%. The stock offers dividend income ($1.10 H1-26) while benefiting from semiconductor industry tailwinds, though margin sustainability and competitive pressures warrant monitoring.
ARKG trades at $43.57, up 1.54% today, with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from positive biotech sector trends including FDA friendliness and M&A activity. However, key oscillators show neutral readings with RSI indicators suggesting overbought conditions near the $45 resistance level.
The biotech ETF outlook remains favorable amid sector strength, though elevated RSI levels indicate potential near-term consolidation. Investment opportunity lies in continued sector momentum, while risks include market volatility and selective investor sentiment toward biotech companies as noted by JPMorgan bankers in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
